Please login to the form below

Not currently logged in
Email:
Password:

Hikma appoints group scientific officer and global head of R&D

Dr Surendera Tyagi joins the pharma group from Fresenius Kabi

Speciality pharmaceutical group Hikma has appointed a group scientific officer and gloval head of R&D in the form of Dr Surendera Tyagi, who will focus on the group’s non-injectables business and will become a member of Hikma’s executive committee.

He joins the pharma group from Fresenius Kabi, where he most recently led its US innovation and development centre.

Prior to this, he served as chief scientific officer for Sabur Pharma, an oncology company that was acquired by Fresenius in 2008.

Tyagi has also held various scientific and regulatory roles at Roche IGEN, Abbott/Hospita and Scwarz Pharma.

He said: “Hikma’s track record of delivering affordable, quality medicines to people who need them is a purpose that I share, and I look forward to accelerating their R&D efforts by advancing and expanding their pipeline.”

22nd January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...
2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....

Infographics